Resetting the Ambition for Biotechnology in the EU
As the new European Parliament meets for its inaugural session in Strasbourg, Belgium, EuropaBio has published its
Biotechnology Industry Manifesto 2019. The manifesto calls upon EU decision makers to reset the ambition for a healthier, more resource efficient, technology driven Europe.
Biotechnology is already a transformative EU asset, says EuropaBio, significantly addressing unmet medical needs, enabling smarter, more efficient use of natural resources, reducing greenhouse gas emissions and improving the quantity and quality of food and feed. But huge potential remains untapped for delivering new and innovative solutions to the United Nations Sustainable Development Goals for 2030.
EuropaBio Secretary General, Joanna Dupont-Inglis commented: “Time is now of the essence in addressing the grand challenges facing Europe and the wider world. The EU Biotech community is already fully engaged in this work and, with the right political support and regulatory framework, can play an even greater role. For this, we need to foster an ecosystem which encourages innovation, builds trust, protects IP, attracts and unlocks investment and develops a coherent EU life sciences and biotechnology strategy.”
EuropaBio is calling on the EU’s new political leadership “to be bold and decisive in its decision making, fostering innovative biotechnology to benefit people and planet.”
Read the full Biotechnology Industry Manifesto 2019
.
Expanding Immune Response Testing to Support Vaccine Development
April 22nd 2025Nigel McCracken, chief operating officer, Virax Biolabs, discusses the expansion of its ViraxImmune platform into areas such as transplant monitoring, vaccine efficacy, latent virus reactivation, and CAR T cell therapy.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Sanofi Advances Mid- to Late-Stage Respiratory Pipeline, Targeting Unmet Need in Asthma, COPD
April 21st 2025New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab advance into chronic rhinosinusitis, chronic obstructive pulmonary disease, and bronchiectasis.
